Patents by Inventor Brian T. Campbell

Brian T. Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 9730937
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 15, 2017
    Assignee: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170107236
    Abstract: A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 29, 2015
    Publication date: April 20, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brian T. Campbell, Guizhen Dong, Joie Garfunkle, Alexander Kim, Olga Ornoski, Dann L. Parker, JR., Subharekha Raghavan, Libo Xu, Zhiquang Yang
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160199375
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: March 18, 2016
    Publication date: July 14, 2016
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 9320739
    Abstract: Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: April 26, 2016
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150246042
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: January 26, 2015
    Publication date: September 3, 2015
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 8969587
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 3, 2015
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140045868
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 13, 2014
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, SHRIPAD S. BHAGWAT, BRIAN T. CAMPBELL, QI CHAO, RAFFAELLA FARAONI, MARK W. HOLLADAY, ANDILIY G. LAI, MARTIN W. ROWBOTTOM, EDUARDO SETTI, KELLY G. SPRANKLE
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 8618289
    Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: December 31, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20110118245
    Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
    Type: Application
    Filed: March 17, 2009
    Publication date: May 19, 2011
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Inhibitors of Akt activity
    Patent number: 7910561
    Abstract: The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: March 22, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeannie M. Arruda, Brian T. Campbell, Nicholas D. P. Cosford, Jacob M. Hoffman, Essa H. Hu, Mark E. Layton, Yiwei Li, Jun Liang, Kevin J. Rodzinak, Tony Siu, Brian A. Stearns, Lida R. Tehrani, Mark T. Bilodeau, Peter J. Manley
  • Inhibitors of Akt Activity
    Publication number: 20080287457
    Abstract: The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.
    Type: Application
    Filed: December 9, 2005
    Publication date: November 20, 2008
    Inventors: Jeannie M. Arruda, Brian T. Campbell, Nicholas D.P. Cosford, Jacob M. Hoffman, Essa H. Hu, Mark E. Layton, Yiwei Li, Jun Liang, Kevin J. Rodzinak, Tony Siu, Brian A. Stearns, Lida R. Tehrani, Mark T. Bilodeau, Peter J. Manley
  • Metabotropic glutamate receptor-5 modulators
    Patent number: 7087601
    Abstract: Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: August 8, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Jeannie Arruda, Celine Bonnefous, Brian T. Campbell, Rowena V. Cube, Benito Munoz, Brian Stearns, Jean-Michel Vernier, Bowei Wang, Xiumin Zhao